Phillip P. Chan's most recent trade in Cytosorbents Corp was a trade of 34,168 Series A Right Warrants (right to buy) done . Disclosure was reported to the exchange on Feb. 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | 24 Feb 2025 | 34,168 | 0 | - | - | Series A Right Warrants (right to buy) | ||
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | 24 Feb 2025 | 34,168 | 1,277,363 (3%) | 0% | 1.1 | 38,610 | Common Stock | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 17 Jan 2025 | 90,832 | 90,832 | - | - | Series A Right Warrants | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | 17 Jan 2025 | 90,832 | 1,243,195 (3%) | 0% | 1 | 90,832 | Common Stock | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | 17 Jan 2025 | 90,832 | 0 | - | - | Subscription Rights (right to buy) | ||
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 17 Jan 2025 | 90,832 | 90,832 | - | - | Series B Right Warrants | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 124,000 | 124,000 | - | - | Stock Option (Right to Buy) | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 96,000 | 1,164,704 (3%) | 0% | 0 | Common Stock | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 129,998 | 129,998 | - | - | Stock Option (Right to Buy) | |
| Cytosorbents Corp | P. Phillip Chan | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.33 per share. | 13 Dec 2023 | 75,188 | 1,068,704 (3%) | 0% | 1.3 | 100,000 | Common Stock |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Dec 2023 | 26,315 | 26,315 | - | - | Common Stock Warrant (Right to Buy) | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2023 | 112,000 | 112,000 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2023 | 87,000 | 1,006,548 (2%) | 0% | 0 | Common Stock | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2023 | 48,000 | 48,000 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Phillip P. Chan | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.88 per share. | 03 Apr 2023 | 30,500 | 927,779 (2%) | 0% | 2.9 | 87,688 | Common Stock |
| Cytosorbents Corp | Phillip P. Chan | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2023 | 30,500 | 0 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.26 per share. | 06 Dec 2022 | 14,291 | 881,570 (2%) | 0% | 1.3 | 18,064 | Common Stock |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.26 per share. | 06 Dec 2022 | 9,850 | 891,420 (2%) | 0% | 1.3 | 12,411 | Common Stock |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.70 per share. | 08 Sep 2022 | 35,000 | 867,279 (2%) | 0% | 1.7 | 59,500 | Common Stock |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 240,000 | 240,000 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 106,000 | 106,000 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 79,000 | 845,130 (2%) | 0% | 0 | Common Stock | |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.85 per share. | 16 Jun 2022 | 2,221 | 768,351 (2%) | 0% | 1.9 | 4,109 | Common Stock |
| Cytosorbents Corp | Phillip P. Chan | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.17 per share. | 09 Jun 2022 | 16,000 | 766,130 (2%) | 0% | 2.2 | 34,784 | Common Stock |
| Cytosorbents Corp | Phillip P. Chan | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 5.25 per share. | 10 Dec 2021 | 5,000 | 753,443 (2%) | 0% | 5.3 | 26,250 | Common Stock |
| Cytosorbents Corp | Phillip P. Chan | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 96,000 | 96,000 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Phillip P. Chan | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 8.99 per share. | 12 Apr 2021 | 72,000 | 769,339 (2%) | 0% | 9.0 | 647,280 | Common Stock |